. 2020 Nov;357:None. doi: 10.1016/j.cellimm.2020.104214

Table 1.

Approaches for ex vivo expansion of human alloantigen-reactive Tregs. APC, antigen presenting cell; DC, dendritic cell; PBMC, peripheral blood mononuclear cell; Treg, regulatory T cell; rh, recombinant human.

Starting population	Stimulator	Ratio	Growth factors	Expansion duration	Expansion fold	Reference
CD4⁺CD25⁺Treg isolated by magnetic beads	Donor derived PBMCs	4:1 PBMCs: Tregs	rhIL-2 + rh IL-15	20 days	780	[12]
CD4⁺CD25⁺CD127^-Treg isolated by magnetic beads	UltraCD40L-activated donor B cells	1:1 B cells: Tregs	rhIL-2 + TGF-β + Sirolimus SRL-7 days only	28 days	~20	[24]
CD4⁺CD25⁺CD127^- Treg isolated by FACS	CD40L-activated donor B cells	4:1 B cells: Tregs	rhIL-2	16 days	50–300	[13]
CD4⁺CD25⁺Treg isolated by magnetic beads	Allogeneic mature DCs	1:10 mDCs: Tregs	rhIL-2 + rh IL-15 + Rapamycin	21 days	8.3	[23]
CD4⁺CD25⁺CD127^- Treg isolated by FACS	Blood or dermal donor derived mature CD1c⁺ DCs	Not reported	rhIL-2	4–6 weeks	Mean numbers ~2.8 × 10⁷	[14]
CD4⁺CD25⁺Treg isolated by magnetic beads	CD40L-expanded B cell lines	10:1 B cells: Tregs	rhIL-2	2–3 weeks	80–120	[15]
CD4⁺CD25⁺CD127^-Treg isolated by magnetic beads	Allogeneic monocytes derived DCs	1:10 DCs: Tregs	rhIL-2 + rh IL-15 + Rapamycin	12 days	8	[25]